Intrastructural help

Edit links
From Wikipedia, the free encyclopedia

Intrastructural help (ISH) is where T and B cells cooperate to help or suppress an immune response gene.[1] ISH has proven effective for the treatment of influenza,[2] rabies related lyssavirus,[3] hepatitis B,[4] and the HIV virus.[5] This process was used in 1979 to observe that T cells specific to the influenza virus could promote the stimulation of hemagglutinin specific B cells and elicit an effective humoral immune response.[2] It was later applied to the lyssavirus and was shown to protect raccoons from lethal challenge.[3] The ISH principle is especially beneficial because relatively invariable structural antigens can be used for the priming of T-cells to induce humoral immune response against variable surface antigens. Thus, the approach has also transferred well for the treatment of hepatitis B and HIV.[5]

Background[edit]

One of the approaches for a protective HIV-1 vaccine is broadly neutralizing antibodies. These antibodies are found in 10-25 % of HIV-1 infected patients.[4] Few of those (worldwide 0.8% of HIV-1 positive individuals) are able to suppress viremia up to a level that is below the detection levels and are so-called "elite controllers" or "long term non-progressors".[5] Most of the conducted vaccine trials were unable to induce protective neutralizing antibodies; even though some protective effects of poly-functional antibodies were observed.[6] These Fc-dependent effects seem to play an important role in disease control as shown by the non-human primate (NHP) experiment.[7][8] In contrast, the results of the adenoviral-based STEP trial suggested a higher susceptibility due to high levels of non-neutralizing poly-functional antibodies and helper T cell proliferation induced by vaccination.[9] In mouse models antibodies from the IgG1 subclass, which were mostly induced by vaccination, were seen to possess a relatively low functionality. Therefore, one objective is to increase the quality of the immune response by the induction of poly-functional antibody sub classes, e.g. IgG2A.[7] However, according to results from animal studies, cytotoxic T cells seem to be mandatory for a protective vaccine. Although this was not detectable in the human trials conducted to-date, it is assumed that reduction of viral loads early after infection can be achieved. Thus the current goal is to avoid uncontrolled T cell proliferation and modulate the humoral immune response towards highly efficient poly-functional monoclonal antibodies.[10]

ISH in HIV treatment[edit]

This vaccination approach aims to induce a protective humoral and also cellular immune response by a two-step immunization scheme. The first step is based on a DNA vaccine vector in order to prime T cells. In the case of HIV, T cells specific for the group-specific antigen (Gag) are stimulated. For the second step a formulation of nano particles or virus-like particles is vaccinated. These particles contain Gag protein and HIV-Env surface protein. These particles can be recognized by B cells and subsequently be internalized, processed and presented on the cell surface on MHC-II, in combination with the primed Gag-specific T cells. This was shown to lead to a strong activation of the B cells and ultimately to the production of Env-specific antibodies by the activated B cells. In HIV research, this method was shown to enhance the specific humoral immune response and at the same time avoid an excess activation of the cellular immune response which could otherwise cause disease progression to thrive. Timewise the priming of T cells for Gag reduces the variation of the viral Env because of the lack of Env specific T cells between priming and second vaccination. This decreases the chances of escape variants developing before the boosting immunization.[10]

Current HIV Research[edit]

One of the key aspects here is the precise modulation of the immune response upon activation. This implies good quantity and quality of induced antibodies but low levels of T cell stimulation to avoid aforementioned increased susceptibility and disease progression. First in vitro and immunization experiments conducted with Simian Immunodeficiency virus (SIV), showed a 10-50 fold increase in Env-specific antibodies of treated mice compared to exosome vaccinated ones.[11] and was also verified for HIV in the mouse model by adoptive transfer experiments.[12] Non-human primate experiments also indicate increased Env Ab titers upon Gag pre-immunization.[13][14] It is likely to assume that these results are transferable to humans as HIV-1 patients with neutralizing antibodies were shown to possess increased numbers of Gag-specific T cells but time wise comparable levels of Env gp120 specific T cells.[12] This points towards a contribution of the intrastructural help to the neutralization ability.

References[edit]

  1. ^ Goodman-Snitkoff, G.; Good, M. F.; Berzofsky, J. A.; Mannino, R. J. (1991-07-15). "Role of intrastructural/intermolecular help in immunization with peptide-phospholipid complexes". The Journal of Immunology. 147 (2): 410–415. doi:10.4049/jimmunol.147.2.410. ISSN 0022-1767. PMID 1712806.
  2. ^ a b Russell, S. M.; Liew, F. Y. (1979-07-12). "T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin". Nature. 280 (5718): 147–148. Bibcode:1979Natur.280..147R. doi:10.1038/280147a0. PMID 317881. S2CID 4257295.
  3. ^ a b Dietzschold, B; Wang, H H; Rupprecht, C E; Celis, E; Tollis, M; Ertl, H; Heber-Katz, E; Koprowski, H (December 1987). "Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein". Proceedings of the National Academy of Sciences of the United States of America. 84 (24): 9165–9169. Bibcode:1987PNAS...84.9165D. doi:10.1073/pnas.84.24.9165. ISSN 0027-8424. PMC 299713. PMID 3480536.
  4. ^ a b Boots, A M; Kusters, J G; van Noort, J M; Zwaagstra, K A; Rijke, E; van der Zeijst, B A; Hensen, E J (September 1991). "Localization of a T-cell epitope within the nucleocapsid protein of avian coronavirus". Immunology. 74 (1): 8–13. ISSN 0019-2805. PMC 1384663. PMID 1718856.
  5. ^ a b c Hraber, Peter; Seaman, Michael S.; Bailer, Robert T.; Mascola, John R.; Montefiori, David C.; Korber, Bette T. (2014). "Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection". AIDS. 28 (2): 163–169. doi:10.1097/qad.0000000000000106. PMC 4042313. PMID 24361678.
  6. ^ Montefiori, David C.; Karnasuta, Chitraporn; Huang, Ying; Ahmed, Hasan; Gilbert, Peter; Souza, De; S, Mark; McLinden, Robert; Tovanabutra, Sodsai (2012-08-01). "Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials". The Journal of Infectious Diseases. 206 (3): 431–441. doi:10.1093/infdis/jis367. ISSN 0022-1899. PMC 3392187. PMID 22634875.
  7. ^ a b Bournazos, Stylianos; Klein, Florian; Pietzsch, John; Seaman, Michael S.; Nussenzweig, Michel C.; Ravetch, Jeffrey V. (2014). "Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity". Cell. 158 (6): 1243–1253. doi:10.1016/j.cell.2014.08.023. PMC 4167398. PMID 25215485.
  8. ^ Costa, Matthew R.; Pollara, Justin; Edwards, Regina Whitney; Seaman, Michael S.; Gorny, Miroslaw K.; Montefiori, David C.; Liao, Hua-Xin; Ferrari, Guido; Lu, Shan (2016-11-15). "Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001". Journal of Virology. 90 (22): 10362–10378. doi:10.1128/jvi.01458-16. ISSN 0022-538X. PMC 5105670. PMID 27630232.
  9. ^ Buchbinder, Susan P.; Mehrotra, Devan V.; Duerr, Ann; Fitzgerald, Daniel W.; Mogg, Robin; Li, David; Gilbert, Peter B.; Lama, Javier R.; Marmor, Michael (2008-11-29). "Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial". Lancet. 372 (9653): 1881–1893. doi:10.1016/S0140-6736(08)61591-3. ISSN 0140-6736. PMC 2721012. PMID 19012954.
  10. ^ a b Temchura, Vladimir; Überla, Klaus (2017-05-01). "Intrastructural help". Current Opinion in HIV and AIDS. 12 (3): 272–277. doi:10.1097/coh.0000000000000358. ISSN 1746-630X. PMID 28422791. S2CID 47544510.
  11. ^ Nabi, Ghulam; Bonsmann, Michael Genannt; Tenbusch, Matthias; Gardt, Oliver; Barouch, Dan H; Temchura, Vladimir; Überla, Klaus (2013). "GagPol-specific CD4+ T-cells increase the antibody response to Env by intrastructural help". Retrovirology. 10 (1): 117. doi:10.1186/1742-4690-10-117. PMC 3874777. PMID 24156704.
  12. ^ a b Bonsmann, Michael Storcksdieck genannt; Niezold, Thomas; Temchura, Vladimir; Pissani, Franco; Ehrhardt, Katrin; Brown, Eric P.; Osei-Owusu, Nana Yaw; Hannaman, Drew; Hengel, Hartmut (2015-11-15). "Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells". The Journal of Immunology. 195 (10): 4861–4872. doi:10.4049/jimmunol.1501377. ISSN 0022-1767. PMID 26466954.
  13. ^ Liang, Xiaoping; Casimiro, Danilo R.; Schleif, William A.; Wang, Fubao; Davies, Mary-Ellen; Zhang, Zhi-Qiang; Fu, Tong-Ming; Finnefrock, Adam C.; Handt, Larry (2005-10-01). "Vectored Gag and Env but Not Tat Show Efficacy against Simian-Human Immunodeficiency Virus 89.6P Challenge in Mamu-A*01-Negative Rhesus Monkeys". Journal of Virology. 79 (19): 12321–12331. doi:10.1128/jvi.79.19.12321-12331.2005. ISSN 0022-538X. PMC 1211517. PMID 16160159.
  14. ^ Liu, Jinyan; O’Brien, Kara L.; Lynch, Diana M.; Simmons, Nathaniel L.; Porte, Annalena La; Riggs, Ambryice M.; Abbink, Peter; Coffey, Rory T.; Grandpre, Lauren E. (2008-11-09). "Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys". Nature. 457 (7225): 87–91. Bibcode:2009Natur.457...87L. doi:10.1038/nature07469. PMC 2614452. PMID 18997770.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Intrastructural_help&oldid=1195569784"